

Brian A. Baldo

# Safety of Biologics Therapy

Monoclonal Antibodies, Cytokines,  
Fusion Proteins, Hormones, Enzymes,  
Coagulation Proteins, Vaccines,  
Botulinum Toxins

 Springer

# Safety of Biologics Therapy



Brian A. Baldo

# Safety of Biologics Therapy

Monoclonal Antibodies, Cytokines,  
Fusion Proteins, Hormones, Enzymes,  
Coagulation Proteins, Vaccines,  
Botulinum Toxins

Brian A. Baldo (Retired)  
AUA(Pharmacy); BSc(Hons); PhD  
Formerly:  
Royal North Shore Hospital of Sydney  
Head, Molecular Immunology Unit  
Kolling Institute of Medical Research and  
University of Sydney  
Sydney, NSW, Australia

ISBN 978-3-319-30470-0      ISBN 978-3-319-30472-4 (eBook)  
DOI 10.1007/978-3-319-30472-4

Library of Congress Control Number: 2016943849

© Springer International Publishing Switzerland 2016

This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed.

The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made.

Printed on acid-free paper

This Springer imprint is published by Springer Nature  
The registered company is Springer International Publishing AG Switzerland

*Dedicated to the memories of my mother  
and father and to Gail MacDiarmid for the  
cherished years of support, partnership,  
and mutual devotion*



# Preface

In writing this book, the author's primary intention was to produce an up-to-date text book on approved biologic therapies as far as that is possible in this time of rapidly evolving and seemingly ever-expanding developments in biotherapeutic research and the introduction of new and novel biopharmaceuticals. Emergence of the disciplines of genomics and proteomics, together with molecular biological approaches to elucidate the functions of single genes, continues to reveal the complexities and multifaceted nature of diseases such as cancer, autoimmunity, and metabolic disorders and to identify potential targets for the development of new drug therapies. Targeted approaches, long practiced in relation to peptide hormones and enzymes, now so often drive the extraordinary interest in, and development of, monoclonal antibody, fusion protein, and cytokine therapies. Added stimulus has been provided by regulatory authorities in efforts to encourage the development of diagnostic agents and treatments for rare diseases previously neglected because of inadequate financial returns from very small markets. In particular, The US Food and Drug Authority (FDA) Office of Orphan Products Development provides incentives for the study and development of products for so-called orphan diseases, that is, diseases with fewer than 200,000 patients in the USA. This initiative has, for example, transformed the extent and nature of the research and development of enzymes as replacement therapies for lysosomal storage diseases and led to the introduction of monoclonal antibody therapy for the rare paroxymal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome by targeting complement C5. These advances, among many others presented in this monograph, would almost certainly not have been made in the absence of recombinant DNA technology, today's sequencing methods, application of modern bioinformatics, and parallel proteome analyses by application of techniques such as mass spectroscopy.

An attempt has been made to cover those biologics that are currently the main product classes with regulatory approval in the USA and/or European Union and which show every indication of remaining important therapies over at least the next decade and beyond. Due to considerations of established therapeutic relevance and space constraints, coverage has been almost totally restricted to products given regulatory approval. This is reflected in the three chapters devoted to monoclonal



antibodies, the dominant biotherapeutic agents in terms of diversity of target recognition and approved indications, and the products with the highest global sales revenue in today's biopharmaceutical market. Although there are well over 300 monoclonal antibodies in development, coverage here at June 2016 is restricted to the 50 (counting alemtuzumab [MabCampath® and Lemtrada®] and Denosumab [Prolia® and Xgeva®] as two not four antibodies) currently approved by the FDA or European Medicines Agency or both. Unsurprisingly, recombinant preparations dominate the different categories of approved biologics, and because of their inherent advantages including production of large quantities of pure human materials without the need to purify crude extracts, their ease of genetic and chemical manipulation to reduce side effects and accentuate or reduce selected properties, consistency of supply, minimal batch-to-batch variation, reduced cost of production, and their safety of manufacture, this is certain to continue. Coverage is extended to the relatively small number of cytokines approved for therapy out of more than 130 of these known pleiotropic immune modulators of immune and inflammatory responses and to the growing list of approved fusion proteins most of which are made up of an effector peptide (such as a cytokine, growth factor, etc.) linked to an antibody Fc fusion partner or human albumin. Known, studied, and used as therapies for many years, peptide and glycoprotein hormones, now mainly as recombinant products, are examined in some detail together with other related and/or modified hormone products produced to effect therapeutic improvements, alter pharmacokinetic and pharmacodynamic properties, or reduce adverse effects. In addition to enzymes as replacement therapies for lysosomal storage diseases, a number of other enzymes indicated for disorders as diverse as cystic fibrosis, Dupuytren's contracture, vitreomacular adhesion, myocardial infarction, and acute lymphocytic leukemia are examined. Descriptions, approved indications, and usage, of 22 approved coagulation or clotting factor preparations, essential for maintaining homeostasis, are reviewed together with the clotting cascade, an emphasis on safety aspects, and new product developments. Vaccination, an indispensable public health measure described as "the greatest triumph of modern immunology and the most successful exploitation of our knowledge of the workings of the immune response," has nevertheless not always been afforded the respect it deserves in modern medical practice. While vaccines are not free of associated adverse events, those that have been recorded together with the known and suspected effects induced by additives and possible contaminants are examined for all 46 approved vaccine preparations presented. Botulinum neurotoxins, surprising in their sheer number of clinical applications (a few approved, many not), which now include muscular, neurologic, gastrointestinal, urologic, ophthalmic, and oropharyngeal disorders, have exceeded the most optimistic early estimates of their usage. This already large list of approved and potential indications is currently being further enlarged by evaluations in off-label treatments outside controlled clinical trials. Such relatively uncontrolled activity is a reminder of the need to remain aware of the potentially extreme toxicity of the botulinum neurotoxins and to record and report adverse events when they occur. In the light of the seemingly exorbitant costs associated with many of today's biologic therapies, follow-on biologics or biosimilars offer the promise of fostering

competition, allowing the treatment of more patients at lower cost, and helping to lower ever-increasing government health costs. Difficulties in achieving the required comparability or similarity, safety evaluations, and eventual regulatory approval are considered in the book's final chapter.

While efforts have been made to unify the text by cross-referencing and interconnecting common or related subjects, no comprehensive and scrupulous referencing to the original literature that is standard for scientific papers has been undertaken since this would have considerably increased the size of the book and been at odds with its intended organization and textbook style. As a reasonable compromise and with the aim of assisting the reader to locate original sources and extend understanding, carefully selected suggestions for Further Reading have been included at the end of each chapter. The chapters on cytokines, fusion proteins, and enzymes are based on the author's previous publications for Springer. These publications, quoted in the Further Reading lists, provide a comprehensive reference list for Chaps. 5, 6, and 9. Further Reading selections for these and other chapters have been selected to guide the interested reader to the most significant studies in the original literature and preview potentially important future developments.

It is with sincere appreciation and thanks that the author acknowledges the skills, dedication, cooperation, and help, given by long-standing collaborator Dr. Nghia H. Pham in the joint preparation of numerous tables and a widely diverse range of figures, many of the latter demonstrating individuality and produced with some artistry as well as relevance, scientific accuracy, and dedication to detail.

In conclusion, with biologic therapies continuing to demonstrate extraordinary growth in the origin and nature of the agents employed, the introduction of new disease targets, the enlarging range of approved indications, and the increasing understanding of each agent's spectrum of associated risks and adverse events, the continued development and innovation seen in biologic therapies over the last few years seem certain to be sustained. Given this ongoing expansion of new knowledge, research, and development in therapeutic biologics, the author remains open and ready to consider all comments in an ongoing effort to remain abreast of new developments, improve the book, and correct any errors.

Sydney, Australia

Brian A. Baldo



# Contents

<b>1</b>	<b>Approved Biologics Used for Therapy and Their Adverse Effects</b> .....	1
	Biologics .....	1
	US Guidelines .....	1
	European Guidelines .....	3
	Biologics and Small Molecule Drugs .....	4
	Protein Therapeutics .....	5
	Some Complexities of Protein Therapeutics:	
	Perceived Advantages and Some Problems .....	6
	The Evolving Biologics Market.....	7
	Adverse Drug Reactions .....	8
	Definitions.....	8
	Terminology: Adverse Reactions and Adverse Events .....	8
	Classification of Adverse Drug Reactions .....	10
	Syndromes That May Be Associated with Biologic Therapies.....	17
	Summary .....	22
	Further Reading .....	26
<b>2</b>	<b>Monoclonal Antibodies: Introduction</b> .....	29
	Monoclonal Antibodies for Therapy .....	29
	Evolution of Therapeutic Monoclonal Antibodies:	
	From Mouse to Man.....	30
	Technological Advances in the Production	
	of Monoclonal Antibodies.....	39
	Hybridoma Technology and Immortalization	
	of Human B Cells.....	39
	Phage Display .....	40
	Transgenic (Knockout) Mice .....	40
	Monoclonal Antibodies from Single Human B Cells	
	by Gene Cloning .....	41

IgG Antibody Subclasses .....	41
Glycosylation of Monoclonal Antibodies .....	43
Antibody-Dependent Cell-Mediated and Complement-Dependent Cytotoxicities .....	45
Nomenclature for Monoclonal Antibodies.....	48
Breakdown of Antibody Type and Approved Indications for the Currently Approved Monoclonal Antibodies .....	49
Antibody-Drug Conjugates.....	52
Future Prospects of Monoclonal Antibody Therapy .....	53
Summary .....	54
Further Reading .....	56
<b>3 Monoclonal Antibodies Approved for Cancer Therapy .....</b>	<b>57</b>
Approved Monoclonal Antibodies for Cancer Therapy.....	58
Catumaxomab .....	65
Blinatumomab.....	66
Monoclonal Antibodies Targeting CD20: Rituximab, Ibritumomab, Ofatumumab, and Obinutuzumab .....	67
Brentuximab Vedotin .....	75
Alemtuzumab.....	78
Monoclonal Antibodies Targeting Epidermal Growth Factor Receptor: Cetuximab, Panitumumab, and Nectinmab .....	79
Bevacizumab.....	88
Ramucirumab.....	93
Monoclonal Antibodies Targeting Human Epidermal Growth Factor 2 (HER2): Pertuzumab, Trastuzumab, and Ado-trastuzumab Emtansine .....	95
Denosumab .....	107
Ipilimumab.....	109
Siltuximab.....	111
Monoclonal Antibodies Targeting Programmed Cell Death Protein 1 (PD-1): Pembrolizumab and Nivolumab .....	113
Dinutuximab .....	117
Daratumumab.....	118
Elotuzumab .....	119
Recent Approval: Atezolizumab .....	120
Range of Side Effects of Monoclonal Antibodies Used for Cancer Therapy .....	120
Types I–IV Hypersensitivities and Cytopenias.....	121
Infusion Reactions and Cytokine Release Syndrome .....	123
Pulmonary Adverse Events.....	124
Cardiac Adverse Events .....	126
Mucocutaneous Reactions to Monoclonal Antibodies Targeted to Epidermal Growth Factor Receptor.....	127

Other Rare Adverse Events Following Antitumor Monoclonal Antibody Therapy .....	128
Summary .....	129
Further Reading .....	138
<b>4 Other Approved Therapeutic Monoclonal Antibodies</b> .....	141
Monoclonal Antibodies Targeted to Human Tumor Necrosis Factor: Adalimumab, Certolizumab Pegol, Infliximab, and Golimumab .....	141
Boxed Warnings and Precautions for Adalimumab, Certolizumab Pegol, Infliximab, and Golimumab .....	142
Adalimumab .....	142
Certolizumab Pegol .....	152
Infliximab .....	155
Golimumab .....	158
Abciximab .....	160
Integrin Recognition by Abciximab .....	160
Indications, Warnings, Precautions, and Adverse Events .....	161
Immunogenicity of Abciximab .....	161
Alemtuzumab .....	162
Basiliximab .....	164
The IL-2 Receptor and Mechanism of Action of Basiliximab .....	164
Basiliximab Indications, Warnings, Precautions, and Adverse Events .....	164
Immunogenicity of Basiliximab .....	166
Belimumab .....	167
BLys and Belimumab .....	167
Belimumab Warnings, Precautions, and Adverse Events .....	168
Immunogenicity of Belimumab .....	169
APRIL, Lupus, and Atacicept .....	169
Canakinumab .....	170
CAPS and the Mechanism of Action of Canakinumab .....	170
CAPS Diseases and Approved Indications for Canakinumab .....	170
Warnings, Precautions, and Adverse Events for Canakinumab .....	171
Denosumab .....	172
Eculizumab .....	173
Approved Indications .....	174
Paroxysmal Nocturnal Hemoglobinuria, Atypical Hemolytic Uremic Syndrome, and Mechanism of Action of Eculizumab .....	175
Warnings, Precautions, and Adverse Events .....	177
Immunogenicity of Eculizumab .....	178
Monoclonal Antibody Integrin Inhibitors: Natalizumab and Vedolizumab .....	178
Natalizumab .....	178
Vedolizumab .....	183

Omalizumab .....	184
Approved Indications .....	185
Mechanism of Action of Omalizumab .....	185
Safety of Omalizumab .....	186
Palivisumab .....	187
Ranibizumab .....	187
Raxibacumab .....	189
Anthrax and Background to the Development of Raxibacumab .....	189
Mechanism of Action of Raxibacumab .....	189
Indications and Usage of Raxibacumab .....	190
Safety of Raxibacumab .....	190
Secukinumab .....	191
Mechanism of Action of Secukinumab .....	191
Approved Indications and Safety of Secukinumab .....	192
Tocilizumab .....	192
IL-6 and Mechanism of Action of Tocilizumab .....	193
Approved Indications and Safety of Tocilizumab .....	193
Ustekinumab .....	197
IL-12 and IL-23 and Immune-Mediated Diseases .....	197
Mechanism of Action of Ustekinumab .....	199
Indications and Safety of Ustekinumab .....	199
Proteinase Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors:	
Alirocumab and Evolocumab .....	200
Alirocumab: Indications and Safety .....	201
Evolocumab: Indications and Safety .....	202
Idarucizumab .....	202
Mechanism of Action of Idarucizumab .....	202
Indications and Safety of Idarucizumab .....	203
Mepolizumab .....	204
Mechanism of Action of Mepolizumab .....	204
Indications and Safety of Mepolizumab .....	204
Recent Approvals: Obiltoxaximab, Ikexizumab, Reslizumab .....	205
Summary .....	205
Further Reading .....	214
<b>5 Cytokines .....</b>	<b>217</b>
Introduction .....	217
General Characteristics .....	217
Classification of Cytokines .....	217
Adverse Effects of Individual Approved Recombinant Cytokine Analogs .....	218
Individual Approved Cytokines .....	220
Interferon Alfa .....	220
Interferon Beta .....	233
Interferon Gamma .....	234

Colony-Stimulating Factors: Filgrastim, Sargramostim, and Tbo-Filgrastim.....	235
Oprelvekin.....	237
Becaplermin .....	238
Palifermin.....	240
Aldesleukin .....	240
Anakinra.....	243
Epoetins.....	245
Bone Morphogenetic Proteins.....	247
Metreleptin.....	249
Ancestim .....	250
Concluding Remarks.....	251
Summary .....	253
Further Reading .....	260
<b>6 Fusion Proteins.....</b>	<b>263</b>
Desired Properties and Composition of Chimeric Fusion Proteins .....	263
Fc Fusion Proteins.....	264
Fc Fusion Proteins as Glycoproteins.....	265
IgG Subclasses of Fc Fusion Proteins: Increasing and Decreasing Effector Function.....	268
Origin, Nature, Mechanism of Action, and Usage of Fc Fusion Proteins .....	268
Etanercept .....	268
Belatacept.....	269
Abatacept .....	274
Rilonacept .....	274
Aflibercept.....	274
Romiplostim.....	275
Alefacept .....	276
Factor VIII Fc Fusion Protein .....	277
Factor IX Fc Fusion Protein.....	277
Dulaglutide.....	278
Atacicept .....	278
Safety of Approved Fc Fusion Proteins .....	278
Etanercept .....	279
Belatacept Safety .....	287
Abatacept .....	289
Rilonacept .....	290
Aflibercept Safety .....	290
Romiplostim.....	292
Alefacept .....	292
Albumin Fusion Proteins .....	293
Albiglutide .....	294
Factor IX Albumin Fusion Protein.....	294



Albumin Fusion Proteins in Late Stage Development..... 294

Albumin Fusion Proteins in the Early Stage of Development..... 295

Denileukin Diftitox ..... 296

The Immunogenicity of Therapeutic Fusion Proteins:  
 Attempts to Help Recognize Patients at Risk ..... 297

Diagnosis of Hypersensitivities to Fusion Proteins,  
 Premedication, and Desensitization ..... 299

Concluding Remarks..... 301

Summary ..... 301

Further Reading ..... 307

**7 Peptide Hormones** ..... 309

Insulin ..... 310

Diabetes Mellitus ..... 311

Production of Insulin..... 312

Structure of Insulin ..... 314

Release of Insulin..... 315

Insulin Binding to Its Receptor and Ensuing Signaling..... 316

Different Available Insulin Preparations..... 316

Sodium-Glucose Co-transporter 2 Inhibitors..... 320

Warnings, Precautions, and Adverse Events  
 Associated with Insulin Use..... 321

Glucagon ..... 326

Structure and Mechanism of Action of Glucagon..... 327

Indications and Adverse Effects of Glucagon..... 328

Glucagon Hypersensitivity..... 328

Glucagon-Like Peptide 1 ..... 329

Glucagon-Like Peptide 2 ..... 330

Glucagon-Like Peptide 1 and the Incretin Effect..... 330

GLP-1 Receptor Agonists ..... 333

Safety of GLP-1 Receptor Agonists..... 335

Immunogenicity of GLP-1 Receptor Agonists ..... 337

Dipeptidyl Peptidase-4 (DPP-4) Inhibitors (Gliptins) ..... 338

Pramlintide ..... 342

Human Growth Hormone ..... 344

Structure and Mechanism of Action of Growth Hormone..... 345

Indications and Usage of Somatropin ..... 347

Adverse Events to Somatropin..... 348

Immunogenicity of Growth Hormone ..... 350

Pegvisomant: A Growth Hormone Receptor Antagonist ..... 350

Insulin-Like Growth Factor 1 ..... 351

Structure and Mechanism of Action ..... 352

IGF-1 and Growth Stimulation ..... 353

Mecasermin..... 353

Somatostatin.....	355
Synthetic Analogs of Somatostatin .....	356
Approved Indications for Somatostatin Analogs .....	358
Warnings and Precautions for Somatostatin Analogs .....	359
Adverse Events to Somatostatin Analogs .....	360
Vasopressin .....	364
Physiologic Actions of Vasopressin .....	364
Vasopressin Gene and Hormone Structure .....	365
Vasopressin Receptors .....	365
Safety of Vasopressin Therapy.....	367
Desmopressin.....	368
Terlipressin.....	369
Vaptans: Vasopressin Receptor Antagonists .....	370
Oxytocin.....	371
Indications.....	371
Oxytocin Structure .....	372
Oxytocin Receptors.....	372
Safety of Oxytocin .....	374
Safety of Carbetocin .....	374
Safety of Atosiban.....	375
Adrenocorticotrophic Hormone .....	376
Structure, Function, and Indications of ACTH .....	376
Adverse Events to Cosyntropin .....	377
Gonadotropin-Releasing Hormone .....	377
Structure of GnRH .....	378
GnRH Neurons and Secretion.....	378
GnRH Receptor.....	380
GnRH Agonists and Antagonists .....	380
Safety of GnRH Analogs .....	382
Parathyroid Hormone.....	383
Structure and Action of Human Parathyroid Hormone.....	386
Parathyroid Hormone Receptors and Signaling.....	387
Safety of Parathyroid Hormone .....	389
Summary .....	390
Further Reading .....	397
<b>8 Glycoprotein Hormones .....</b>	<b>401</b>
Follicle-Stimulating Hormone .....	401
Structure and Mechanism of Action .....	402
Indications and Usage of Follicle-Stimulating Hormone .....	403
Warnings, Precautions, and Adverse Events.....	404
Luteinizing Hormone .....	405
Structure and Mechanism of Action .....	405
Indications and Usage of Lutropin Alfa.....	406

Warnings, Precautions, and Adverse Events	
Associated with Lutropin Alfa .....	406
Human Chorionic Gonadotropin.....	407
Structure and Mechanism of Action .....	408
Indications and Usage of Chorionic Gonadotropin .....	409
Warnings, Precautions, and Adverse Events .....	410
Thyroid-Stimulating Hormone.....	411
Structure and Mechanism of Action .....	412
Indications and Usage of Thyrotropin Alfa.....	413
Warnings, Precautions, and Adverse Events .....	413
Thyrostimulin.....	414
Summary .....	414
Further Reading .....	417
<b>9 Enzymes Approved for Therapy.....</b>	<b>419</b>
Introduction.....	419
Toward Successful Enzyme Replacement Therapy:	
Gaucher Disease.....	420
Approved Enzymes as Replacement Therapy	
for Lysosomal Storage Diseases .....	420
Other Enzymes Approved for Therapy .....	435
Tissue Plasminogen Activators .....	437
Asfotase Alfa.....	438
Asparaginase .....	438
Collagenase .....	439
Dornase Alfa .....	440
Glucarpidase .....	440
Hyaluronidase .....	441
Ocriplasmin.....	443
Pegademase Bovine .....	444
Pegloticase .....	444
Rasburicase .....	445
Streptokinase.....	445
Safety of Approved Enzymes Used as Therapy	
for Lysosomal Storage Diseases .....	447
Agalsidase Beta for Fabry Disease .....	447
Alglucosidase Alfa for Pompe Disease.....	447
Recombinant Enzymes Used to Treat Gaucher Disease:	
Imiglucerase, Taliglucerase Alfa, and Velaglucerase Alfa.....	448
Sebelipase Alfa for Lysosomal Acid Lipase Deficiency .....	450
Laronidase for MPS I.....	450
Idursulfase for MPS II .....	450
Elosulfase Alfa for MPS IVA.....	451
Galsulfase for MPS VI.....	451

Adverse Events Caused by Other Approved Enzymes .....	452
Tissue Plasminogen Activators .....	452
Asfotase Alfa .....	454
L-Asparaginase .....	454
Collagenase .....	455
Dornase Alfa .....	455
Glucarpidase .....	456
Hyaluronidase .....	456
Ocriplasmin .....	457
Pegademase Bovine .....	458
Pegloticase .....	458
Rasburicase .....	459
Streptokinase .....	459
Antibody Responses to Enzymes .....	460
Other Therapies for Lysosomal Storage Diseases .....	464
Stem Cell Transplantation .....	465
Substrate Reduction Therapy .....	465
Chaperones .....	466
Gene Therapy .....	466
Living with Enzyme Replacement Therapy .....	466
Summary .....	468
Further Reading .....	476
<b>10 Blood Coagulation .....</b>	<b>479</b>
Platelet Activation and von Willebrand Factor .....	479
The Kallikrein-Kinin System and Coagulation .....	489
The Clotting Cascade .....	490
Factor XII and Coagulation .....	494
Factor VIII .....	495
B-Domain Deleted Recombinant Factor VIII .....	495
Turoctocog Alfa .....	496
Simoctocog Alfa .....	497
Susoctocog Alfa .....	498
Clotting Factor Fusion Proteins .....	498
Factor VIII Fc Fusion Protein .....	498
Factor IX Fc Fusion Protein .....	499
Factor IX Albumin Fusion Protein .....	500
Safety of Approved Blood Coagulation Preparations .....	500
Inhibitors in Hemophilia and Bypass Therapy .....	500
Factor VIIa .....	502
Factor VIII Full Length Preparations .....	503
Moroctocog Alfa: B-Domain Depleted Factor VIII .....	503
Other B-Domain-Depleted Factor VIII Preparations:	
Turoctocog Alfa, Simoctocog Alfa and Susoctocog Alfa .....	504
Factor VIII Fc Fusion Protein .....	504

Factor IX Fusion Proteins .....	505
Factor XIII A-Subunit .....	505
Von Willebrand Factor/Coagulation Factor VIII Complex.....	506
Antihemophilic Factor/Von Willebrand Factor Complex .....	506
Recombinant Von Willebrand Factor .....	507
Factor Eight Inhibitor Bypassing Activity (FEIBA), Anti-inhibitor Coagulant Complex .....	507
Prothrombin Complex Concentrate .....	507
Fibrinogen Preparations to Control Bleeding .....	507
Summary .....	508
Further Reading .....	512
<b>11 Vaccines</b> .....	515
Vaccines: Definition, Attenuation, and Subunit, Acellular, Carbohydrate, Conjugate and DNA Vaccines.....	515
Currently Approved Vaccines: Description, Indications, Warnings, Precautions, and Adverse Events .....	536
“Allergy”/Adverse Reactions to Vaccines and Added Components .....	540
Allergic Reactions to Egg Proteins in Vaccines.....	541
Allergic Reactions to Gelatin in Vaccines.....	543
Aluminium Adjuvants .....	544
Reactions to Other Vaccine Additives.....	546
Cutaneous Reactions to Vaccinations .....	549
Injection Site Reactions .....	549
Cutaneous Hypersensitivity Reactions to Vaccines .....	551
Other Dermatologic Reactions.....	552
Summary .....	552
Further Reading .....	556
<b>12 Botulinum Neurotoxins</b> .....	559
Botulinum Neurotoxin Serotypes .....	559
Toxin Structure and Mechanisms of Action.....	560
Structure of Botulinum Neurotoxin BoNT .....	560
Structure and Absorption of Botulinum Neurotoxin Complex .....	561
Mechanism of Action at the Neuromuscular Junction.....	563
Therapeutic Applications of Botulinum Neurotoxin.....	565
Nomenclature and Equivalence of Different Botulinum Toxin Preparations .....	565
Approved Indications of FDA Registered Botulinum Neurotoxin Preparations.....	569
Other Possible Indications for Botulinum Neurotoxins.....	572
Adverse Effects of Botulinum Neurotoxin .....	572
Warnings and Precautions .....	574
Adverse Events Following Therapeutic and Cosmetic Use of Botulinum Neurotoxin.....	575

- Immunogenicity and Clinical Relevance of Botulinum Neurotoxin ..... 579
  - Anti-Neurotoxin Antibodies..... 579
  - Detection and Measurement of Neutralizing Antibodies..... 580
- Summary ..... 582
- Further Reading ..... 585
- 13 Biosimilars** ..... 587
  - The Continuing Evolution of Biosimilars..... 587
  - Naming of Biosimilars and Pharmacovigilance Considerations ..... 589
  - Biobetters ..... 593
  - Biosimilars in the Immediate Future..... 593
  - Summary ..... 594
  - Further Reading ..... 596
- Index**..... 597

# Chapter 1

## Approved Biologics Used for Therapy and Their Adverse Effects

### Biologics


“Biologics” in this book refer to therapies that are prepared from materials made or expressed in living organisms. They may simply be isolated proteins such as enzymes and blood products or, as is increasingly the case, preparations produced by recombinant DNA technology. Biologics, sometimes also referred to as “biotherapeutics” or “biopharmaceuticals,” are covered by a number of different definitions depending on the perspective of the interested party, with researchers from different disciplines, biotechnologists, chemists, clinicians, legislators, and regulatory agencies, to name only a few, requiring or excluding aspects that reflect their interest and involvement. Whereas a biologist, chemist, or clinician may see a biologic used for therapy as material derived from, or related to, a living organism, for example, cells, cell extracts, or molecules composed of protein, peptide, complex carbohydrate, lipid, or nucleic acid, a regulatory authority will also consider how such agents are to be classified and assessed for characterization, manufacturing, and control; product development; identity, purity, and potency; and so on. In other words, in a regulatory context, “biologics” does not necessarily correspond to common usage or usage in everyday medical research and likewise for the terms “biotechnology medicine/drug,” “biological medical product/drug,” and “biopharmaceuticals,” used outside the regulatory environment.

### *US Guidelines*

In 1902, in the Biologics Control Act passed by the US Congress, biologics and biologic products were defined as “any virus, therapeutic serum, toxin, antitoxin or analogous product applicable to the prevention, treatment or cure of diseases or injuries of man.” Although this definition has changed over time, uncertainties, difficulties, and impreciseness have remained for agencies, many groups, and individuals

concerned and/or working with biologic therapeutics. In particular, the term “analogous” has remained undefined and open to varying degrees of relatedness. Since 1902, the Congress has expanded the list of biologics to include other products including vaccines, blood products, and some other proteins, but polypeptides prepared by chemical synthesis remained excluded. In the 1938 Federal Food, Drug, and Cosmetic Act, “drug” was defined as a substance for the investigation, prevention, or cure of disease, but no guidance was forthcoming to distinguish biologic and non-biologic drugs. However, in 1944, the Congress did declare that a requirement for a new drug application (NDA) did not apply to biologics. The latter are now marketed under the provisions of the Public Health Service Act requiring a Biologics License Application (BLA) showing the agent is “safe, pure, and potent.” By 1947, hormones had been excluded from the list of biologics, and with the arrival of the new age of biotechnology in the mid- to late 1980s, US Food and Drug Administration (FDA) issued a policy statement saying that agents would be regarded as biologics “based on the intended use of each product on a case-by-case basis.” Following an Intercenter Agreement, in June 2003, the FDA transferred some of the therapeutic biologic products that had formerly been reviewed and regulated by the Center for Biologics Evaluation and Research (CBER) to the Center for Drug Evaluation and Research (CDER). Therapeutic biological products transferred to the CDER include monoclonal antibodies (mAbs), cytokines, fusion proteins, some enzymes, growth factors, non-vaccine immunomodulators, and therapeutic proteins derived from animals, plants, and microorganisms and recombinant versions of these products. Remaining with the CBER are cellular products of human, animal, or bacterial origin; gene therapy products such as nucleic acids, viruses and genetically engineered microorganisms; vaccines; allergenic extracts; antitoxins, antivenoms, and venoms; and blood, blood components, and plasma-derived products. The approved biologics covered in this monograph are comprised of therapeutic biological products from both the CDER and CBER lists. In 2012, the FDA issued a draft guidance addressing and distinguishing the long-standing proposed differences between proteins, peptides, and chemically synthesized polypeptides. A protein was defined as any alfa amino acid polymer with a specific defined sequence that is greater than 40 amino acids in size. From this definition, it followed that peptides have fewer than 40 amino acids and are therefore not proteins. A chemically synthesized polypeptide was defined as an alfa amino acid polymer that is made entirely by chemical synthesis and has fewer than 100 amino acids. Until the draft guidance is finalized, these definitions can be seen as proposals, but regardless of the definitions finally declared and adopted and for the coverage of biologics in this volume, peptides with less than 40 amino acids and chemically synthesized polypeptides (whether they contain fewer or more than 100 amino acids) with regulatory approval for therapeutic use in humans will be considered first and foremost as biologics regardless of size or method of preparation. In keeping with this approach, peptide hormones (Chap. 7) and glycoprotein hormones (Chap. 8) are logically included in the coverage of biologics licensed for marketing as approved therapeutic agents. Note that regardless of the method of manufacture, hormones require a NDA. In summary, in the US, distinguishing a product from other drugs and classifying it as a biologic on the basis of existing





**Fig. 1.1** Phases in biological product development under an investigational new drug (IND) application leading to clinical trials with evaluations for safety and efficacy, a Biologics License Application (BLA) and ultimately licensing and marketing. Reproduced from Vatsan RS, Bross PF, Liu K, et al. *J Immunother Cancer* 2013;1:5. <http://www.immunotherapyofcancer.org/content/1/1/5>, an open access article distributed under the terms of the Creative Commons Attribution License

definitions is not straightforward since detailed legislated guidance has never been provided. Recently, the FDA has mentioned the application of a so-called bright-line rule for distinguishing proteins suggesting a much-needed shift from ad hoc to jurisdictional decision-making.

From the early preliminary specifications for product characterization, Fig. 1.1 summarizes the phases in biological product development under an investigational new drug (IND) application leading on to clinical trials with evaluations for safety and efficacy, a BLA, and ultimately licensing and marketing.

### *European Guidelines*

From a 2001 Directive of the European Parliament and the Council of Six on the community code relating to medicinal products for human use, “biological medicines” are defined as “products, the active substance of which is a biological substance.” In turn, a “biological substance” is defined as “a substance that is produced by or extracted from a biological source and that needs for its characterization and the determination of its quality a combination of physico-chemical-biological testing, together with the production process and its control.” In the European Union, the European Medicines Agency (EMA) defines a “biological medicinal product” as “a protein or nucleic acid-based pharmaceutical substance used for therapeutic or in vivo diagnostic purposes, which is produced by means other than direct extraction from a native (nonengineered) biological source.” This definition essentially appears to restrict “biological medicinal products” to recombinant preparations including mAbs, cytokines, fusion proteins, some hormones (such as insulin, glucagon, growth hormone), enzymes (e.g., alteplase and enzymes used for enzyme replacement therapy), and coagulation proteins (factors VIIa, VIII, IX, XIII, and antithrombin).